Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$65.42 USD
+0.15 (0.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.42 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Gilead Sciences, Inc. [GILD]
Reports for Purchase
Showing records 481 - 500 ( 521 total )
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Lower than expected performance by HIV franchise remains a serious concern.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2010 AASLD Abstract Titles Review - Second Wave Including Late-Breakers
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology / Biopharmaceuticals -2010 AASLD Abstract Titles Review - First Wave Without Late Breakers
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Can Btripla Deliver the Promise - AIDS Conf Abstract Review
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Btripla vs. Atripla and Q2 Earnings Next; Lowering PT to $40.
Provider: WEDBUSH SECURITIES INC.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Unimpressive Q1:10 Earnings and EASL; Negative Impact of Healthcare Reform among Others; Lowering PT to $47
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K